Cabio Biotech (Wuhan) Revenue

In the year 2025, Cabio Biotech (Wuhan) had annual revenue of 574.88M CNY with 3.47% growth. Cabio Biotech (Wuhan) had revenue of 146.86M in the quarter ending December 31, 2025, a decrease of -12.82%.

Revenue

574.88M

Revenue Growth

+3.47%

P/S Ratio

5.67

Revenue / Employee

1.02M

Employees

574

Market Cap

3.26B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	574.88M	19.29M	3.47%
Dec 31, 2024	555.59M	111.79M	25.19%
Dec 31, 2023	443.80M	10.38M	2.39%
Dec 31, 2022	433.42M	82.32M	23.44%
Dec 31, 2021	351.11M	27.65M	8.55%
Dec 31, 2020	Pro	Pro	Pro
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Guangdong VTR Bio-Tech	830.87M
Shanghai Hile Bio-Technology	246.35M
Shanghai Model Organisms Center	421.26M
Suzhou Fushilai Pharmaceutical	439.57M
Landfar Bio-medicine	125.47M
Beijing Kawin Technology Share-Holding	1.15B
Yantai Zhenghai Biotechnology	347.60M
Novoprotein Scientific	151.51M

Revenue Rankings